MiMedx Group Inkomsten in het verleden
Verleden criteriumcontroles 2/6
MiMedx Group heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 61.9%, terwijl de Biotechs-industrie de winst zag groeien met 33.8% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 10.8%. Het rendement op eigen vermogen van MiMedx Group is 12.6%, en het heeft een nettomarge van 7.9%.
Belangrijke informatie
61.86%
Groei van de winst
62.12%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.04% |
| Inkomstengroei | 10.81% |
| Rendement op eigen vermogen | 12.64% |
| Nettomarge | 7.88% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking Alpha
Narratiefupdate • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
Nieuw narratief • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.
Nieuw narratief • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.Narratiefupdate • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.Narratiefupdate • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.Narratiefupdate • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.Narratiefupdate • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.Narratiefupdate • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.Analyseartikel • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Analyseartikel • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...Analyseartikel • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Analyseartikel • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analyseartikel • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...Analyseartikel • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...
Nieuw narratief • Sep 24
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.Analyseartikel • May 21
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
MiMedx Group, Inc. ( NASDAQ:MDXG ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Analyseartikel • May 14
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Opbrengsten en kosten
Opbrengsten en kosten
Hoe MiMedx Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 389 | 31 | 259 | 16 |
| 31 Dec 25 | 419 | 49 | 266 | 15 |
| 30 Sep 25 | 393 | 41 | 254 | 14 |
| 30 Jun 25 | 364 | 32 | 239 | 13 |
| 31 Mar 25 | 352 | 40 | 221 | 13 |
| 31 Dec 24 | 349 | 42 | 216 | 12 |
| 30 Sep 24 | 343 | 79 | 210 | 11 |
| 30 Jun 24 | 340 | 79 | 209 | 11 |
| 31 Mar 24 | 335 | 68 | 216 | 12 |
| 31 Dec 23 | 321 | 56 | 216 | 13 |
| 30 Sep 23 | 309 | 19 | 215 | 6 |
| 30 Jun 23 | 295 | 2 | 219 | 8 |
| 31 Mar 23 | 281 | -18 | 225 | 10 |
| 31 Dec 22 | 268 | -27 | 221 | 13 |
| 30 Sep 22 | 261 | -34 | 216 | 22 |
| 30 Jun 22 | 256 | -28 | 209 | 20 |
| 31 Mar 22 | 258 | -19 | 202 | 19 |
| 31 Dec 21 | 242 | -18 | 199 | 10 |
| 30 Sep 21 | 260 | -35 | 223 | 16 |
| 30 Jun 21 | 261 | -83 | 233 | 15 |
| 31 Mar 21 | 246 | -88 | 231 | 13 |
| 31 Dec 20 | 248 | -83 | 240 | 12 |
| 30 Sep 20 | 256 | -73 | 212 | 11 |
| 30 Jun 20 | 281 | -8 | 210 | 10 |
| 31 Mar 20 | 294 | -17 | 233 | 11 |
| 31 Dec 19 | 299 | -26 | 265 | 11 |
| 30 Sep 19 | 315 | -54 | 270 | 13 |
| 30 Jun 19 | 314 | -67 | 287 | 14 |
| 31 Mar 19 | 342 | -48 | 295 | 15 |
| 31 Dec 18 | 359 | -30 | 295 | 16 |
| 30 Sep 18 | 354 | 41 | 275 | 15 |
| 30 Jun 18 | 352 | 59 | 260 | 16 |
| 31 Mar 18 | 333 | 65 | 235 | 17 |
| 31 Dec 17 | 321 | 65 | 220 | 18 |
| 30 Sep 17 | 303 | 35 | 216 | 18 |
| 30 Jun 17 | 283 | 21 | 205 | 15 |
| 31 Mar 17 | 264 | 15 | 192 | 14 |
| 31 Dec 16 | 222 | 0 | 172 | 14 |
| 30 Sep 16 | 227 | 20 | 168 | 11 |
| 30 Jun 16 | 212 | 23 | 154 | 10 |
| 31 Mar 16 | 200 | 27 | 144 | 9 |
| 31 Dec 15 | 187 | 29 | 133 | 8 |
| 30 Sep 15 | 175 | 20 | 126 | 8 |
| 30 Jun 15 | 160 | 17 | 115 | 8 |
Kwaliteitswinsten: MDXG heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (7.9%) MDXG } zijn lager dan vorig jaar (11.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: MDXG is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 61.9% per jaar laten groeien.
Versnelling van de groei: De winstgroei MDXG is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.
Winst versus industrie: MDXG had het afgelopen jaar een negatieve winstgroei ( -23.2% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Biotechs ( 43% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 12.6% ) van MDXG wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 21:31 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
MiMedx Group, Inc. wordt gevolgd door 11 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |